Anagrelide HCL en es it fr

Anagrelide HCL Brand names, Anagrelide HCL Analogs

Anagrelide HCL Brand Names Mixture

  • No information avaliable

Anagrelide HCL Chemical_Formula


Anagrelide HCL RX_link

Anagrelide HCL fda sheet

Anagrelide_HCL FDA

Anagrelide HCL msds (material safety sheet)

Anagrelide_HCL MSDS

Anagrelide HCL Synthesis Reference

No information avaliable

Anagrelide HCL Molecular Weight

256.088 g/mol

Anagrelide HCL Melting Point

280 oC

Anagrelide HCL H2O Solubility

Very slightly soluble

Anagrelide HCL State


Anagrelide HCL LogP


Anagrelide HCL Dosage Forms

Capsules (0.5 mg or 1 mg)

Anagrelide HCL Indication

For the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.

Anagrelide HCL Pharmacology

Anagrelide is a drug used for the treatment of essential thrombocytosis (ET; essential thrombocythemia). It works by inhibiting the maturation of megakaryocytes into platelets. The exact mechanism of action is unclear, although it is known to be a potent (IC50 = 36nM) inhibitor of phosphodiesterase-III.

Anagrelide HCL Absorption

No information avaliable

Anagrelide HCL side effects and Toxicity

There are no reports of overdosage with anagrelide, however thrombocytopenia, which can potentially cause bleeding, is expected from overdosage. Single oral doses of anagrelide at 2,500, 1,500 and 200 mg/kg in mice, rats and monkeys, respectively, were not lethal. Symptoms of acute toxicity were: decreased motor activity in mice and rats and softened stools and decreased appetite in monkeys.

Anagrelide HCL Patient Information

Anagrelide HCL Organisms Affected

Humans and other mammals